The in vitro activities of eight quinolones against 115 coryneform bacteria (20 Corynebacteriumjeikeium, 15 Corynebacterium minutissimum, 15 Corynebacterium striatum, 25 Corynebacterium urealyticum, 10 Corynebacterium xerosis, 10 Corynebacterium group ANF-1, 10 Corynebacterium group 12, and 10 Listeria monocytogenes) were determined. The MICs of ciprofloxacin, ofloxacin, and sparfloxacin for 90%o of C. jeikeium, C. urealyticum, and C. xerosis isolates tested were >16 ,ug/ml. Those of BAY Y 3118 and clinafloxacin against these species were 0.5 and 1 to 2 ,ig/ml, respectively. The MICs for 90% of all 115 strains tested were 0.5 ,ug/ml for BAY Y 3118, 1 ,ug/ml for clinafloxacin, 2 ,ig/ml for E-5068, 4 gIg/ml for E-5065, and >16 ,ug/ml for ciprofloxacin, ofloxacin, sparfloxacin, and E-4868. An in-house microdilution method was used for susceptibility testing. We followed the guidelines described by the National Committee for Clinical Laboratory Standards (7), with the exception that we used cation-supplemented MuellerHinton broth containing 0.5% Tween 80 (MHT80). Twofold dilutions across a range of 0.015 to 16 ,ug/ml for all eight quinolones were tested. Bacteria from cultures grown on Columbia agar with 5% percent sheep blood for 20 to 24 h were suspended in MHT80 to a concentration of about 108 CFU/ml. This suspension was diluted to obtain 5 x 104 CFU per well. The final volume in each well of the microtiter plate was 100 pLI. Plates were inoculated and were incubated aerobically at 35°C for 18 h or, in the case of plates containing C. jeikeium and C. urealyticum, for 24 h, because with both species there was no visible growth in the control wells without antibiotics at 18 h. The MIC was determined to be the lowest concentration of antimicrobial agent that inhibited visible growth.MICs (range and MICs for 50% [MIC50] and 90% [MIC90] of isolates tested) and the percentage of strains that were inhibited at different concentrations of antibiotics are presented in Table 1. Considering all 115 strains, MIC90s were 0.5 I,g/ml for BAY Y 3118, 1 jig/ml for CLI, 2 ,ug/ml for E-5068, 4 ,ug/ml for E-5065, and >16 jig/ml for CIP, SPA, OFL, and E-4868.The breakpoints of the National Committee for Clinical Laboratory Standards (7) for CIP and OFL were c1 and .2 ,ug/ml, respectively, for susceptibility and .4 and .8 ,ig/ml, respectively, for resistance. Considering these values, an initial report (6) showed that all strains of C. jeikeium were susceptible to CIP, but a more recent study (9) showed that only 36% of C. jeikeium strains were susceptible to this fluoroquinolone. Similarly, initial data concerning C. urealyticum (10) showed that all strains tested were susceptible to OFL; in a later report (2), only 47% of strains were susceptible to OFL and 40% were susceptible to CIP. In our study, 40% of C. jeikeium strains were susceptible to CIP and 50% were susceptible to OFL; in the case of C. urealyticum, 44% of strains were susceptible to CIP and 48% were susceptible to OFL. It is difficult to know whether these discr...